Harpreet Singh

Harpreet Singh, MD

Chief medical officer, Precision for Medicine

Latest Stories
Guest Editorial

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login